

Research Opportunities



The School of Cancer Sciences at the University of Birmingham has an international reputation in the following areas:

- **Cancer Cell Biology and Epigenetics**

[\(/research/activity/mds/domains/Cancer/cancer-cell-biology-epigenetics/index.aspx\)](http://research/activity/mds/domains/Cancer/cancer-cell-biology-epigenetics/index.aspx)

- **Cancer Genetics and DNA Damage**

[\(/research/activity/mds/domains/Cancer/cancer-genetics-dna-](http://research/activity/mds/domains/Cancer/cancer-genetics-dna-damage/index.aspx)

[damage/index.aspx\)](http://research/activity/mds/domains/Cancer/cancer-genetics-dna-damage/index.aspx)

- **Cellular, Immune and Gene Therapy for Cancer** ([/research/activity/mds/domains/Cancer/cell-immune-gene-therapy/index.aspx](http://research/activity/mds/domains/Cancer/cell-immune-gene-therapy/index.aspx))
- **Structural Biology and Biomarkers** ([/research/activity/mds/domains/Cancer/structural-biology-and-biomarkers/index.aspx](http://research/activity/mds/domains/Cancer/structural-biology-and-biomarkers/index.aspx))
- **Tumour Immunology** ([/research/activity/mds/domains/Cancer/tumour-immunology/index.aspx](http://research/activity/mds/domains/Cancer/tumour-immunology/index.aspx))
- **Viral Oncology** ([/research/activity/mds/domains/Cancer/viral-oncology/index.aspx](http://research/activity/mds/domains/Cancer/viral-oncology/index.aspx))

The School's research capacity is facilitated by access to a wide range of 'state of the art' technologies including nuclear magnetic resonance (NMR) for structural and metabolomic analysis (housed in the **Henry Wellcome Building** ([/facilities/nmr/index.aspx](http://facilities/nmr/index.aspx))), proteomics and protein chip analysis, gene expression profiling, next-generation sequencing, confocal microscopy and a flow cytometry cell sorting service.

The application of these technologies in conjunction with a very large patient base accessible through our **Clinical Trials Unit** ([/research/activity/mds/trials/crctu/index.aspx](http://research/activity/mds/trials/crctu/index.aspx)) provides a unique opportunity to identify new cancer biomarkers and to develop novel therapeutic approaches.

For enquiries contact our **PhD Co-ordinator** (<mailto:palmery@adf.bham.ac.uk>).